Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-naphthyl‑1‑acetamido boronic acid alanine is a synthetic small molecule belonging to the class of naphthalene derivatives containing a boronic acid moiety. It has been studied primarily as an experimental transition-state analog inhibitor of serine proteases, such as alpha-chymotrypsin and subtilisin Carlsberg. The compound acts by forming a covalent tetrahedral adduct with the catalytic serine residue in the enzyme active site, mimicking the transition state of peptide bond hydrolysis and thereby inhibiting enzymatic activity. This mechanism makes it useful for probing stereoselectivity and binding interactions in protease research[5][7]. There are no approved therapeutic indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-naphthyl-1-acetamido boronic acid alanine.